Curia Global has refinanced its senior secured credit facilities.
Through this transaction, the company will extend the maturities of its secured credit facilities, while also gaining access to incremental capital.
By refinancing, Curia hopes to position itself for continuted growth as a contract research, development and manufacturing organisation within the global biopharmaceutical market.
Recently, Curia expanded the commercial manufacturing capacity at its Rensselaer, New York facility, which has enhanced the company's complex active pharmaceutical ingredient (API) manufacturing capabilities.
The company has also invested into its Albuquerque, New Mexico facility, significantly bolstering its fill-finish capabilities for customers in the key US market.
Curia plans to further expand this section of its business through further expansion to its Glasgow, UK site — which will more than double the current GMP batch size once completed.
"The refinancing demonstrates the confidence our lenders and investors have in Curia,” said CEO of Curia, Philip Macnabb.
“The new credit facility will enable us to continue investing in key growth projects that enhance our differentiated capabilities and deliver greater value for our customers.”